In this article, we will be taking a look at the 5 most oversold large cap stocks to buy. If you wish to learn about more, visit 8 Most Oversold Large Cap Stocks to Buy.
5. Insulet Corporation (NASDAQ:PODD)
RSI Value: 28.87
Market Capitalization: $10.68 billion
Insulet Corporation (NASDAQ:PODD) is one of the most oversold stocks.
TheFly reported on May 7 that PODD saw its valuation outlook revised as Goldman Sachs reduced its price target to $237 from $277 while maintaining a Buy rating on the shares. The firm noted that the company’s first-quarter results and updated guidance initially appeared strong, but concerns emerged regarding the growth trajectory after second-quarter U.S. revenue guidance came in below full-year expectations, and annual targets were only reiterated despite a first-quarter beat. Management also attributed the slower-than-expected start to the year to stronger seasonality effects linked to insurance deductible resets, which impacted early demand trends.
Moreover, earlier, on May 4, Insulet Corporation (NASDAQ:PODD) reported the enrollment of the first participant in its EVOLVE study evaluating a fully closed-loop automated insulin delivery system for individuals with type 2 diabetes. The study represents an important step in advancing next-generation diabetes management technology. The system is designed to automatically adjust insulin dosing through an advanced algorithm trained on both real-world and simulated patient data, aiming to improve safety and glucose control while reducing the burden on patients and healthcare providers. The development reflects PODD’s continued focus on innovation in diabetes care solutions.
Insulet Corporation (NASDAQ:PODD) is a medical device company based in Acton. It develops the Omnipod tubeless insulin delivery system, including Omnipod 5, which helps people with diabetes manage insulin more easily and effectively.
4. L3Harris Technologies, Inc. (NYSE:LHX)
RSI Value: 26.90
Market Capitalization: $55.82 billion
L3 Harris Technologies, Inc. (NYSE:LHX) is among the most oversold stocks.
TheFly reported on May 4 that LHX saw its valuation outlook adjusted as Bernstein reduced the price target to $405 from $435 while maintaining an Outperform rating on the shares. The revision came after the company’s April 30 first-quarter earnings release, which exceeded expectations on both earnings and revenue. Earnings per share came in at $2.72 compared with consensus estimates of $2.53, while revenue reached $5.7 billion versus expected $5.4 billion.
On April 30, L3 Harris Technologies, Inc. (NYSE:LHX) disclosed that it has confidentially filed a draft Form S-1 registration statement with the U.S. Securities and Exchange Commission. The filing relates to a potential initial public offering of common stock for its missile solutions business segment. Key details such as the number of shares to be offered and the expected price range have not yet been determined.
The company noted that the proposed offering remains subject to market conditions, regulatory review, and completion of the SEC review process. The move represents an early step in evaluating a possible separation or public listing of the business unit, depending on future approvals and market environment.
L3 Harris Technologies, Inc. (NYSE:LHX) is a U.S. aerospace and defense company based in Melbourne. It provides communication, surveillance, electronic warfare, and mission systems across air, land, sea, and space for government and commercial customers.
3. Brown & Brown, Inc. (NYSE:BRO)
RSI Value: 26.23
Market Capitalization: $19.13 billion
Brown & Brown, Inc. (NYSE:BRO) is among the best oversold stocks to invest in.
TheFly reported on May 7 that BRO was upgraded by Citigroup from Neutral to Buy, while the price target remained unchanged at $70. The firm also raised its outlook on several insurance brokerage companies, pointing to valuation as the primary driver behind the change. It noted that current cyclical pressures affecting growth are expected to moderate over the coming quarters, which could create broader upside potential across the sector as conditions normalize and support improved investor returns.
Separately, earlier, on April 28, Brown & Brown, Inc. (NYSE:BRO) reported first-quarter results showing earnings per share of $1.39, slightly above analyst expectations of $1.36. Revenue for the quarter came in at $1.90 billion, also modestly ahead of consensus estimates of $1.89 billion. Management highlighted that employees continued to support clients effectively despite a challenging environment for growth across the insurance sector. The results reflected steady operational performance, with both top and bottom line figures exceeding market forecasts, indicating resilience in the company’s core brokerage operations during the period.
Brown & Brown, Inc. (NYSE:BRO) is a global insurance brokerage based in Daytona Beach. It provides insurance, reinsurance, and risk management solutions for businesses, governments, and individuals through a decentralized network of offices worldwide.
2. Stryker Corporation (NYSE:SYK)
RSI Value: 22.06
Market Capitalization: $109.33 billion
Stryker Corporation (NYSE:SYK) is one of the most oversold stocks to invest in.
TheFly reported on May 4 that SYK saw its valuation outlook revised as Truist reduced the price target to $330 from $380 while maintaining a Hold rating on the stock. The adjustment followed updates to the firm’s financial model after the company’s first quarter results. The revision also reflected disruptions from a cyber-related incident in the first quarter, which affected the timing and flow of earnings. Additionally, the lowered target incorporated broader valuation pressure, with reduced multiples across large-cap medical technology peers contributing to the updated outlook for the stock.
Moreover, previously, on April 30, Stryker Corporation (NYSE:SYK) reaffirmed its fiscal 2026 outlook, keeping adjusted earnings per share guidance in the range of $14.90 to $15.10, slightly above consensus expectations. The company also maintained its projection for organic net sales growth between 8.0% and 9.5%, supported by modestly positive pricing trends. Management noted that foreign exchange is expected to provide a slight tailwind to both revenue and adjusted earnings per share, assuming current currency levels persist, indicating stable operational expectations for the year ahead.
Stryker Corporation (NYSE:SYK) is a global medical technology company based in Portage. It develops products in orthopaedics, surgical equipment, and neurotechnology, serving patients worldwide with innovative healthcare solutions.
1. Alcon Inc. (NYSE:ALC)
RSI Value: 21.89
Market Capitalization: $30.77 billion
Alcon Inc. (NYSE:ALC) is one of the most oversold stocks on this list.
TheFly reported on May 8 that ALC saw its valuation outlook revised as Barclays reduced the price target to $78 from $90 while reiterating an Equal Weight rating on the shares.
Separately, on May 5, Alcon Inc. (NYSE:ALC) reported its first-quarter 2026 performance, showing strong underlying momentum across its eye care portfolio. Sales reached $2.7 billion, increasing 10% on a reported basis and 6% in constant currency compared with the prior year period. Growth was supported by new product launches in both surgical and vision care segments, including advanced intraocular lens platforms and contact lens innovations, along with strength in dry eye treatments.
The corporation’s core operating income rose year over year, reflecting improved efficiency and higher sales volumes, although reported operating income declined due to investments in new product commercialization, tariffs, and restructuring-related costs. Core earnings per share increased to $0.85, while reported EPS was $0.39, affected by prior-year investment gains. Cash generation remained stable, with operating cash flow improving modestly. The company also maintained shareholder returns through a dividend and authorized a new $1.5 billion share repurchase program.
Alcon Inc. (NYSE:ALC) is a global eye care company based in Geneva and the world’s largest in ophthalmic devices. It provides surgical and vision care products for conditions like cataracts, glaucoma, and retinal diseases, serving patients in over 140 countries.
While we acknowledge the potential of ALC to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ALC and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
